POSTERS SESSIONS On–site information
The Strolling Poster sessions, take place during the following slots:
- July 15th 2025 from 17.30 to 19.00
- July 16th 2025 from 18.00 to 19.00
Posters are located in Poster Area inside the Boulevard Room (Boulevard Level). Poster Presenters must attend for the whole duration of their session. It’s mandatory to respect the timing as detailed in the following scheme.
Each poster presenter will be given 3 minutes to introduce the scientific paper, followed by a short discussion with the chairs. Posters are listed below alphabetically accordingly to first author. On each panel on-site you will find the Poster # as listed here. Please respect the poster # indications when you hang posters.
We kindly remind you that Rising Stars and Oral Presenters are requested to prepare and display the poster on posters panel. No discussion is scheduled for these categories during the Strolling Poster Sessions.
Tuesday, 15th July 2025 from 17.30 to 19.00
Session 1: Basic Science
Chairs: W. Jin-fu (China) – Steven Taylor (USA)
×
Search :| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Benjamin Diggins | Benjamin Diggins | 0 | 01 | Anti-inflammatory and clinical effects of oral resveratrol supplementation in bronchiectasis |
| 2 | Masaki Fujita | Masaki Fujita | 0 | 02 | Possible animal model of bronchiectasis? Chronic Pseudomonas aeruginosa infection provoked enlargement of small bronchus lumen in CCSP-deficient mice. |
| 3 | Rebecca Hull | Rebecca Hull | 0 | 03 | Targeted Multiplex PCR for Characterising Infection Dynamics in Bronchiectasis |
| 4 | Geonhui Min | Geonhui Min | 0 | 04 | Exploring Immune Dysfunction in Bronchiectasis: A Focus on Natural Killer Cells using Single-Cell Transcriptomes |
| 5 | Patricia Namubiru | Patricia Namubiru | 0 | 05 | Functional and phenotypic neutrophil characteristics in bronchiectasis in adult humans. |
| 6 | Shital Vishnu Patil | Shital Vishnu Patil | 0 | 06 | Microbiological and Pathophysiological Profile in Cases with Recurrent Exacerbation of Bronchiectasis: A Two-Center Experience |
| 7 | Craig Schofield | Craig Schofield | 0 | 07 | A single cell RNA sequencing pipeline to assess airway inflammation using induced sputum samples from a prospective cohort of children with bronchiectasis |
| 8 | Xiyue Shen | Xiyue Shen | 0 | 08 | First Nationwide Screening of Cystic Fibrosis Among Chinese Bronchiectasis Patients: Distinct Clinical and Genetic Profiles with Therapeutic Implications. |
| 9 | Hans Van der Wall | Hans Van der Wall | 0 | 09 | Strong correlations between location of Bronchiectasis and scintigraphic sites of lobar pulmonary micro-aspiration of gastoesophageal refluxate |
| 10 | Yimin Zhu | Yimin Zhu | 0 | 10 | Profiling DPP-1 signalling networks underlying lung immune defence |
Session 2: Comorbidities & Difficult Cases
Chairs: W. Basil (Switzerland) – Yong.hua Gao (China)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | William Flowers | Harriet Caterson | 0 | 11 | Unmasking disease in ulcerative colitis-associated bronchiectasis after treatment with vedolizumab |
| 2 | Shital Patil | Shital Patil | 0 | 12 | Role of nebulised amikacin as an â€adjunct’ to standard care in recurrent exacerbation Bronchiectasis during acute care hospitalization and follow-up period of 52 weeks: A two-tertiary care center study |
| 3 | Louis Chai | Louis Chai | 0 | 13 | Bronchiectasis and Recurrent Infections in Thymoma Patients Attributable to Anti-Cytokine Autoantibodies |
| 4 | William Good | William Good | 0 | 14 | Are we missing sinus disease in bronchiectasis? A sub-study of the Bactek-O trial. |
| 5 | Dawkins Paul | Jeremy Ishi | 0 | 15 | How do comorbidities affect outcomes in the New Zealand bronchiectasis population? |
| 6 | Christine Lu | Christine Lu | 0 | 16 | Routine pathology testing prior to bronchoscopy: Limited clinical impact with significant economic and environmental costs |
| 7 | Dilara O.Topcu | Dilara O.Topcu | 0 | 17 | Impact of the February 6,2023 Earthquake-Induced Environmental Pollution on Exacerbation Rates in Patients with Bronchiectasis |
| 8 | Shital Patil | Shital Patil | 0 | 18 | Clinical Benefit Analysis of Erdosteine plus azithromycin in comparsion to standard care in preventing exacerbation in recovered cases of acute exacerbation of Bronchiectasis: A long-term Comparative Efficacy Study |
| 9 | Kirsty Watson | Kirsty Watson | 0 | 19 | The treatable traits approach is highly acceptable and a positive experience for patients in a regional Australian bronchiectasis outpatient clinic |
Session 3: Diversity
Chairs: Lucy Burr(Australia) – Charles Feldman (South Africa)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Shereen Sharafaddin Alemam | Shereen Sharafaddin Alemam | 0 | 20 | Chronic Bronchiectasis Complicated by Common Variable Immunodeficiency (CVID): A Case Study of Multidisciplinary Management" |
| 2 | Eleni Bacopanos | Eleni Bacopanos | 0 | 21 | Morbidity and mortality burden from bronchiectasis in the United Kingdom: An observational cohort study |
| 3 | Subash Heraganahally | Dayna Duncan | 0 | 22 | A clinical approach to the diagnosis and management of Bronchiectasis in adult Aboriginal patients in the Top End Northern Territory Australia |
| 4 | Heraganahally Subash | Dayna Duncan | 0 | 23 | Bronchiectasis Pocket Guide |
| 5 | Jamie R. Felzer | Jamie R. Felzer | 0 | 24 | Sociodemographic Factors Associated with Health Outcomes in a Sample of the U.S. Bronchiectasis and Nontuberculous Mycobacteria Research Registry |
| 6 | Timothy Howarth | Timothy Howarth | 0 | 25 | The Indigenous Bronchiectasis Assessment Scale - IBAS |
| 7 | Shereen Sharafaddin Alemam | Shereen Sharafaddin Alemam | 0 | 26 | Comprehensive Diagnostic and Management Approach in a Case of Bilateral Bronchiectasis with Hemoptysis in a Heavy Smoker |
| 8 | Eleni Bacopanos | Eleni Bacopanos | 0 | 27 | Bronchiectasis mortality trends across Europe between 2011 – 2018. |
| 9 | Weijie Guan | Mingxin Shi | 0 | 28 | Blood eosinophil counts, airway infections and inhaled antibiotic treatment in bronchiectasis |
Session 4: Epidemiology & Registries
Chairs: Pamela J. McShane (USA) – Raja Dhar (India)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Jacob Christensen | Jacob Christensen | 0 | 29 | Sunshine Coast Hospital and Health Service Bronchiectasis Registry: First local insights into an increasing healthcare burden |
| 2 | Alexander Geyer | Alexander Geyer | 0 | 30 | Reproductive Lifespan and Post-menopausal Bronchiectasis in U.S. Postmenopausal Women: An investigation of the Women’s Health Initiative Cohort |
| 3 | George Solomon | Emily Henkle | 0 | 31 | Treatment patterns by exacerbation history in adults with bronchiectasis: data from the U.S. Bronchiectasis and NTM Research Registry |
| 4 | Doreen Addrizzo-Harris | Christina Hunt | 0 | 32 | U.S. BRONCHIECTASIS AND NTM CARE CENTER NETWORK: Improving the Diagnosis and Treatment of Bronchiectasis and Nontuberculous Mycobacterial Lung Disease |
| 5 | Eunchae Kim | Eunchae Kim | 0 | 33 | Tailored AI Model for the Prediction of Severe Acute Exacerbation in an Asian |
| 6 | Jack Roberts | Jack Roberts | 0 | 34 | Medicare and Pharmaceutical Benefit Scheme utilisation in Australians with Bronchiectasis: A report of linked data from the Australian Bronchiectasis Registry. |
| 7 | Catherine Runge | Catherine Runge | 0 | 35 | Respiratory vaccination practices and infection experiences of Australian adults living with bronchiectasis |
| 8 | Michal Shteinberg | Michal Shteinberg | 0 | 36 | Adults with paediatric-onset bronchiectasis (POBE) have greater disease severity compared to those with adult-onset bronchiectasis (AOBE): A multicenter EMBARC registry study |
| 9 | Lidia Perea | Oriol Sibila | 0 | 37 | The frequent exacerbator phenotype in bronchiectasis revisited: Data from the European Bronchiectasis Registry (EMBARC) |
| 10 | George Solomon | Christina Thornton | 0 | 38 | The Impact of Proton Pump Inhibitor (PPI) Use on Exacerbation Rates in Patients with Bronchiectasis: An Analysis of the US Bronchiectasis and NTM Research Registry |
Session 5: Infections
Chairs: Gregory Tino (USA) – Doreen Addrizzo-Harris (USA)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Qaiser Akram | Qaiser Akram | 0 | 39 | Isolation of Multidrug Resistant Bacteria from hospitalized Bronchiectasis patients in Developing Countries |
| 2 | Ophir Bar-On | Ophir Bar-On | 0 | 40 | The Impact of Nebulised Fucose/Galactose on Pseudomonas aeruginosa Airway Infection |
| 3 | Angelou Castro | Angelou Castro | 0 | 41 | Respiratory viral pathogens during exacerbation of airway disease among adult Aboriginal Australians with bronchiectasis in the Top End Northern Territory Australia |
| 4 | Timothy Howarth | Timothy Howarth | 0 | 42 | Sputum antibacterial sensitivity and resistance patterns among adult Aboriginal Australians with Bronchiectasis in the Top End Northern Territory Australia |
| 5 | Debora Kidanu | Debora Kidanu | 0 | 43 | Non-Cystic Fibrosis Bronchiectasis: Clinical Experience from Gold Coast University Hospital |
| 6 | Emma Ledger | Emma Ledger | 0 | 44 | A paradoxical role of antibodies driving complement-mediated inflammation in Pseudomonas aeruginosa pulmonary infections |
| 7 | Arjuman Sharmin | Arjuman Sharmin | 0 | 45 | Microbiological profile of sputum cultures in patients with severe bronchiectasis: a cross-sectional study |
| 8 | Kellie Strickland | Kellie Strickland | 0 | 47 | Population diversity and antimicrobial resistance profiling of Pseudomonas aeruginosa isolated from Australians with bronchiectasis |
| 9 | Joshua Taverner | Joshua Taverner | 0 | 48 | Systematic review of clinical practice guidelines to identify vaccination recommendations for adults living with chronic lung disease |
| 10 | Harry Thompson | Harry Thompson | 0 | 49 | Pushing the boundaries of virtual wards? Medication regimes traditionally considered high risk for home administration delivered safely via a virtual ward, and the potentially under-considered trauma of long inpatient stays |
| 11 | Kazuya Tone | Kazuya Tone | 0 | 50 | Pulmonary nocardiosis with a nodular-bronchiectatic pattern: A potential cause and aggravator of bronchiectasis |
Session 6: NTM 1
Chairs: Stefano Aliberti (Italy) – Kozo Morimoto (Japan)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Hind Al-Abbasi | Hind Al-Abbasi | 0 | 51 | The impact of the introduction of the Cepheid Xpert MTB/XDR on mycobacterium tuberculosis clinical management in Western Australia |
| 2 | Melinda M Ashcroft | Melinda M Ashcroft | 0 | 52 | The rising incidence of nontuberculous mycobacterial infections in First Nations People in Queensland, Australia 2001–2024. |
| 3 | Desilia Atikawati | Desilia Atikawati | 0 | 53 | Nontuberculous Mycobacterial Pleuritis in Congestive Heart Failure and Hypothyroid Patient |
| 4 | Atsushi Funauchi | Atsushi Funauchi | 0 | 54 | Strain-Level Concordance Between Gastric Aspirate and Sputum Samples in Pulmonary Non-Tuberculous Mycobacterial Disease: A Retrospective Analysis |
| 5 | Kazuki Hashimoto | Kazuki Hashimoto | 0 | 55 | Rapid and Comprehensive Identification of Nontuberculous Mycobacteria from Sputum: NALC-Seq |
| 6 | Shaun Kang | Shaun Kang | 0 | 56 | Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease |
| 7 | Daisy Lu | Daisy Lu | 0 | 57 | Epidemiology and clinical significance of NTM isolates at a tertiary centre in Victoria, Australia. |
| 8 | Eriko Morino | Eriko Morino | 0 | 58 | Pulmonary NTM epidemiology in Japan-Analysis of Medical Claim from National Database 2012-2019 |
| 9 | Kirby Patterson-Fahy | Kirby Patterson-Fahy | 0 | 59 | In vitro efficacy of sulbactam-durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates |
| 10 | Dorothy Hui Lin Ng | Dorothy Hui Lin Ng | 0 | 60 | Supportive Care Gaps in Bronchiectasis Patients with NTM-PD: A Retrospective Study |
| 11 | Kazuki Ono | Kazuki Ono | 0 | 61 | Characteristics and Prognosis in Patients with Bronchiectasis Receiving Long-Term Oxygen Therapy |
| 12 | Jotam G. Pasipanodya | Jotam G. Pasipanodya | 0 | 62 | Role of Rifampin in the treatment of Pulmonary Mycobacterium avian Complex disease: a systematic review and analyses of target attainment |
Wednesday, 16th July 2025 from 18.00 to 19.00
Session 7: Microbiota
Chairs: Sanjay Chotirmall (India) – Steven Taylor (USA)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Tim Baird | Tim Baird | 1 | 01 | Using Meta-Omics to Advance Precision-Based Bronchiectasis Management |
| 2 | Ria Thompson | Ria Thompson | 1 | 02 | Gut Microbiome Signatures Discriminate Nontuberculous Mycobacterial Pulmonary Disease Patients Requiring Treatment From Those With Stable Disease |
| 3 | Park Jinkyeong | Park Jinkyeong | 1 | 03 | Bacterial Profiles in Inhaler Devices after 30 Days of Use by Patients with Non-Cystic Fibrosis Bronchiectasis |
| 4 | Arjuman Sharmin | Arjuman Sharmin | 1 | 04 | Sputum microbiology in severe bronchiectasis: A cross-sectional study |
| 5 | Wen-Wen Wang | Wen-Wen Wang | 1 | 05 | Pseudomonas aeruginosa-Driven Airway Dysbiosis and Machine Learning Prediction of Acute Exacerbations in Non-Cystic Fibrosis Bronchiectasis |
| 6 | Kazuma Yagi | Kazuma Yagi | 1 | 07 | The Impact of Microbiome on the Pathophysiology following Early-life Respiratory Syncytial Virus Infection |
Session 8: NTM 2
Chairs: Jae-Joon Yim (South Korea) – Charles Daley (USA)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Stephanie Sutjipto | Stephanie Sutjipto | 1 | 08 | Management of Refractory Pulmonary Mycobacterium abscessus Infection in a Patient with Bronchiectasis: A Case Experience |
| 2 | Shera Tan | Shera Tan | 1 | 09 | A case of Disseminated Mycobacterium Kansasii Infection with Interferon-ÉŁ Auto-antibodies |
| 3 | Heeral Thakkar | Heeral Thakkar | 1 | 10 | Tigecycline Rechallenge for Pulmonary Mycobacterium abscessus Infection Following Hemorrhagic Pancreatitis: A Case Report |
| 4 | Kirby Patterson-Fahy | Kirby Patterson-Fahy | 1 | 11 | Does lignocaine effect growth of nontuberculous mycobacteria? |
| 5 | Fumiya Watanabe | Fumiya Watanabe | 1 | 12 | A pharmacokinetic-pharmacodynamic modeling approach to optimize ethambutol dosage based on in vitro time-kill assay against Mycobacterium avium |
| 6 | Adrifen Berti Akbar | Adrifen Berti Akbar | 1 | 13 | Concurrent Malignant Pleural Mesothelioma with Pulmonary-Pleural Effusion Due to Non-Tuberculous Mycobacteria (NTM); a Rare Case Report |
| 7 | Daniel Hicks | Daniel Hicks | 1 | 14 | Adverse events leading to Treatment Withdrawal and Interruption in Mycobacteroides abscessus pulmonary disease |
| 8 | Hyung-Jun Kim | Seyoung Jung | 1 | 15 | Clinical Significance of Discordant ESR and CRP Levels in Nontuberculous Mycobacterial Pulmonary Disease |
| 9 | Youngmok Park | Jihoon Kim | 1 | 16 | Adverse Drug Reactions During the Treatment of Nontuberculous Mycobacterial Pulmonary Disease: a Systematic Review and Meta-analysis |
Session 9: Paediatric
Chairs: Ahmad kantar (Italy) – Bernadette Prentice (Australia)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Alana Ainsworth | Alana Ainsworth | 1 | 17 | Prospective ten year follow-up of an early intervention versus control study for children with severe bronchiolitis or pneumonia. |
| 2 | Crystal Bourke | Crystal Bourke | 1 | 18 | Lung clearance index is more sensitive than spirometry to detect lung function impairment in children and adolescents with bronchiectasis |
| 3 | Patrick A. Flume | Patrick A. Flume | 1 | 19 | Incidence and potential underlying aetiologies of paediatric bronchiectasis in the US: 2018–2022 |
| 4 | Catherine A. Gilchrist | Catherine A. Gilchrist | 1 | 20 | BRONCHIECTASIS EXACERBATIONS IN CHILDREN: CAN HOSPITAL STAYS BE SHORTER? |
| 5 | Grace Hendriks, Jordan Trunfio | Grace Hendriks | 1 | 21 | Bringing physiotherapy to First Nations children with chronic lung conditions in remote NT communities. |
| 6 | Victoria Irons | Victoria Irons | 1 | 22 | Are we prescribing the correct antibiotics for positive respiratory cultures from our children with bronchiectasis? |
| 7 | Miriam Manga | Miriam Manga | 1 | 23 | Koira4Rukahukahu: Lungs4Life: The development of a preventive program for chronic respiratory disease. |
| 8 | Hannah O'Farrell | Hannah O'Farrell | 1 | 24 | Gene expression profiling of peripheral blood identifies systemic T-cell and neutrophilic immune response in paediatric bronchiectasis |
| 9 | Laura Rensford | Laura Rensford | 1 | 25 | Physical Activity Levels in Children with Bronchiectasis Living in Counties Manukau, New Zealand. |
| 10 | Katherine Rose | Katherine Rose | 1 | 26 | Are we completing the recommended first-line investigations for children with bronchiectasis at Starship Hospital? |
Session 10: PCD
Chairs: Claire Hogg (UK) – Catherine Byrnes (New Zealand)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Megan Frohlich | Megan Frohlich | 1 | 27 | Seeing the Unseen: Regional Lung Function Assessment in PCD and non-PCD Bronchiectasis using a Novel XV Scanner |
| 2 | Gil Herzberg | Moshe Heching | 1 | 28 | Use of rhDNase in Primary Ciliary Dyskinesia Bronchiectasis |
| 3 | Stephanie March | Stephanie March | 1 | 29 | From the Paddock to the Hospital Room: Raising a Child with Primary Ciliary Dyskinesia in Rural Australia |
| 4 | Caitlin Meechan | Caitlin Meechan | 1 | 30 | Optimising Primary Ciliary Dyskinesia Screening in Adult Bronchiectasis. The value of nasal Nitric Oxide and PICADAR scoring. |
| 5 | Felix C. Ringshausen | Felix C. Ringshausen | 1 | 31 | Creating evidence for the use of HypErtonic saLine in People with Primary Ciliary Dyskinesia – the multicenter, randomized, double-blind, crossover proof-of-concept clinical trial HELP-PCD |
Session 11: Physiotherapy & Allied Healthcare
Chairs: Rebecca Keating (Australia) – Annemarie Lee (Australia)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Shereen Sharafaddin Alemam | Shereen Sharafaddin Alemam | 1 | 32 | Effectiveness of Airway Clearance Techniques in Bronchiectasis Management |
| 2 | George M. Solomon | Christina Feir | 1 | 33 | High frequency chest wall oscillation (HFCWO) data in the Bronchiectasis and Nontuberculous Mycobacteria (NTM) Research Registry (BRR) |
| 3 | Carly Turner | Carly Turner | 1 | 34 | Feasibility of Electrical Impedance Tomography in assessing short-term effects of airway clearance techniques in adults with bronchiectasis, an observational study |
| 4 | Tamara Lazzarin | Tamara Lazzarin | 1 | 35 | Healthcare access for children with bronchiectasis across an expansive geographical area: Analysis of inclusive paediatric physiotherapy service across metropolitan, regional and remote Queensland. |
| 5 | Anmol Kaur Manjit Singh | Anmol Kaur Manjit Singh | 1 | 36 | Pulmonary Rehabilitation in Chronic Bronchiectasis: A Case Report on Sustained Improvements Through Individualized Therapy |
| 6 | Jennifer Phillips | Jennifer Phillips | 1 | 37 | Active cycle of breathing technique, oscillating-PEP therapy or walking with huffing during a bronchiectasis exacerbation |
| 7 | Mitchell Taylor | Mitchell Taylor | 1 | 38 | Effectiveness of a stepwise model of airway clearance techniques in bronchiectasis: a prospective cohort study |
| 8 | Carly Turner | Carly Turner | 1 | 39 | Web-based resources for healthcare professionals and individuals with bronchiectasis: A scoping review |
| 9 | Elizabeth Webb | Elizabeth Webb | 1 | 40 | Exploring the barriers and enablers of airway clearance therapy and exercise amongst adults with bronchiectasis: a patient perspective |
Session 12: Treatments and New Drugs
Chairs: Lucy Morgan (Australia) – Jennifer Pollock (UK)
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Tim Baird | Sushil Agwan | 1 | 41 | Efficacy, Safety, Cost and Antimicrobial Resistance Potential of Long-term Inhaled Colistimethate Sodium in Bronchiectasis: A Real-World Regional Australian Single-Centre Experience |
| 2 | Timothy Aksamit | Timothy Aksamit | 1 | 42 | Lung Function in Patients With Non-Cystic Fibrosis Bronchiectasis By Prespecified Subgroups in the Phase 3, Randomized, Double-Blind, Placebo-Controlled Aspen Trial |
| 3 | Aowen Zhuang | Gary P. Anderson | 1 | 43 | Targeting the Jagged-1/Notch pathway for the treatment of muco-obstructive lung diseases |
| 4 | Julia Bashford | Julia Bashford | 1 | 44 | CERTAIN Study: Ceftolozane/tazobactam continuous infusion for outpatient treatment of exacerbations of Cystic Fibrosis and Bronchiectasis |
| 5 | William Flowers | Harriet Caterson | 1 | 45 | Reducing the treatment burden for people with bronchiectasis: a protocol for deprescribing inhaled corticosteroids |
| 6 | James Chalmers | James Chalmers | 1 | 46 | Efficacy of Brensocatib in Patients with Eosinophilic Inflammation in Bronchiectasis: An Analysis of the ASPEN Trial |
| 7 | James D. Chalmers | James D. Chalmers | 1 | 47 | Results from a Phase II study (AIRLEAF®) of the dipeptidyl peptidase 1 (cathepsin C) inhibitor BI 1291583 in adults with bronchiectasis |
| 8 | Presanth Nair Janathanan | Presanth Nair Janathanan | 1 | 48 | Barriers to Guideline-Directed Therapy for Stable Non- Cystic Fibrosis Bronchiectasis in Australia and New Zealand: A Narrative Review |
| 9 | Kughanishah Jeyabalan | Kughanishah Jeyabalan | 1 | 49 | From Exacerbations to Relief: Harnessing Biologics in the Dual Challenge of Severe Asthma and Bronchiectasis |
| 10 | Xue-shan Li | Xue-shan Li | 1 | 50 | Bacterial load, respiratory symptoms and inhaled antibiotic treatment in adults with bronchiectasis |
| 11 | James D. Chalmers | James D. Chalmers | 1 | 51 | Study design of a Phase III study (AIRTIVITY®) of the novel dipeptidyl peptidase 1 (cathepsin C) inhibitor BI 1291583 in people with bronchiectasis |
| 12 | Katie Rice | Katie Rice | 1 | 52 | Impact of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on bone density in patients with Cystic Fibrosis: a retrospective study. |
| 13 | George Solomon | George Solomon | 1 | 53 | Initial assessment of the “Chronic Airways Assessment Test” (CAAT™) as a drug development tool in bronchiectasis |
Session 13: Rising Stars & Oral Presenters
Search :
| # | Presenter | First Author | Day | Abs # | Title |
|---|---|---|---|---|---|
| 1 | Michal Shteinberg | Marcus A. Mall | 2 | 01 | A Phase II study (CLAIRAFLY®) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase 1 (cathepsin C) inhibitor BI 1291583 in adults with cystic fibrosis bronchiectasis |
| 2 | Laura Cooper | Laura Cooper | 2 | 02 | Economic evaluation of a physiotherapy-led community-based airway clearance service for people with chronic lung conditions: single group interrupted time series |
| 3 | James D. Chalmers | Damian G. Downey | 2 | 03 | Safety and efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: Phase 1 results and Phase 2b trial design |
| 4 | Robert Flowers | Robert Flowers | 2 | 04 | Racial and Ethnic Disparities in Bronchiectasis Outcomes in an Urban Safety-Net Hospital |
| 5 | Kiyoharu Fukushima | Kiyoharu Fukushima | 2 | 05 | Molecular Epidemiological Surveillance for Non-Tuberculous Mycobacterial Pulmonary Disease: A Single Center Prospective Cohort Study. |
| 6 | Koji Furuuchi | Koji Furuuchi | 2 | 06 | Gene Expression Profiling of Airway Epithelium in Mycobacterium avium Complex Lung Disease |
| 7 | Rebecca Hull | Rebecca Hull | 2 | 07 | Airway Interleukin-7 is a biomarker of exacerbation risk in patients with Pseudomonas aeruginosa infection in bronchiectasis |
| 8 | Merete B Long | Merete B Long | 2 | 08 | Results from the GREAT-2 phase II randomised placebo-controlled trial of the bispecific monoclonal antibody gremubamab targeting Pseudomonas aeruginosa in people with bronchiectasis |
| 9 | Ellie Maas | Ellie Maas | 2 | 09 | Exome sequencing in a large cohort of primary ciliary dyskinesia: comprehensive evaluation of known genes and identification of new potential candidates |
| 10 | Francesca Nicola | Francesca Nicola | 2 | 10 | Unraveling the pathogenicity of Mycobacterium abscessus in cystic fibrosis pulmonary epithelial cells and mouse models of respiratory infection. |
| 11 | Lidia Perea | Lidia Perea | 2 | 11 | CC16 as a biomarker of bronchial infection and disease severity in bronchiectasis |
| 12 | Jack Roberts | Jack Roberts | 2 | 12 | Development and validation of a bronchiectasis child-specific quality of life instrument: The BC-QoL |
| 13 | Sarah Walker | Sarah Walker | 2 | 13 | Alpha-1 Antitrypsin Deficiency and Asthma: Modelling a Candidate Bronchiectasis Risk Nexus |
| 14 | Le-Le Wang | Le-Le Wang | 2 | 14 | Factors associated with hemoptysis in patients with non-cystic fibrosis bronchiectasis: cross-sectional analysis of data from the BE-China Registry |
| 15 | Xiyue Shen | Yingzhou Xie | 2 | 15 | Identification of a Response Regulator Controlling Antibiotic Persister Formation in Pseudomonas aeruginosa |
| 16 | Gary P. Anderson | Aowen Zhuang | 2 | 16 | Targeting the Jagged-1/Notch pathway for the treatment of muco-obstructive lung diseases |
